This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Generic drugmakers' deals with US DOJ complicate Humana bellwether case

By Chris May ( June 15, 2026, 21:13 GMT | Comment) -- As Humana moves toward the first trial in massive generic drug price-fixing litigation, deals between the US Department Justice and drugmakers to resolve criminal charges have raised questions about how limited admissions of guilt should be presented to a jury in civil cases.As Humana moves toward the first trial in massive generic drug price-fixing litigation, deals between the US Department Justice and drugmakers to resolve criminal charges have raised fresh questions about how limited admissions of guilt should be presented to a jury in civil cases....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login